StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

BioLineRx total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

BioLineRx's total debt was $4.48M at Jun 30, 2026. For fiscal 2025 it was $4.48M, up 0.0% from the year before. The highest annual figure on record is $4.48M in fiscal 2024.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.48M0.0%
FY2024Dec 31, 2024$4.48M+42.4%
FY2023Dec 31, 2023$3.15M+104.0%
FY2022Dec 31, 2022$1.54M-44.1%
FY2021Dec 31, 2021$2.76M-10.8%
FY2020Dec 31, 2020$3.09M+14.9%
FY2019Dec 31, 2019$2.69M+200.8%
FY2018Dec 31, 2018$895.00K+862.4%
FY2017Dec 31, 2017$93.00K0.0%
FY2016Dec 31, 2016$93.00K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.48M-58.0%
Q4 FY2025Dec 31, 2025$4.48M+42.4%
Q2 FY2025Jun 30, 2025$4.48M+45.5%
Q4 FY2024Dec 31, 2024$4.48M+190.5%
Q2 FY2024Jun 30, 2024$10.66M+951.9%
Q4 FY2023Dec 31, 2023$3.15M+14.1%
Q2 FY2023Jun 30, 2023$3.08M-8.2%
Q4 FY2022Dec 31, 2022$1.54M-50.1%
Q2 FY2022Jun 30, 2022$1.01M-64.7%
Q4 FY2021Dec 31, 2021$2.76M+2.4%
Q2 FY2021Jun 30, 2021$3.35M+40.0%
Q4 FY2020Dec 31, 2020$3.09M+245.5%
Q2 FY2020Jun 30, 2020$2.87M+2982.8%
Q4 FY2019Dec 31, 2019$2.69M+2794.6%
Q2 FY2019Jun 30, 2019$2.40M+2475.3%
Q4 FY2018Dec 31, 2018$895.00K–
Q2 FY2018Jun 30, 2018$93.00K–
Q4 FY2017Dec 31, 2017$93.00K–
Q4 FY2016Dec 31, 2016$93.00K–

More BioLineRx figures

See a number that looks wrong?